Company Filing History:
Years Active: 2003-2004
Title: The Innovations of Luciano G. Frigeri: Pioneering Mitochondrial Research
Introduction
Luciano G. Frigeri, an accomplished inventor based in San Diego, CA, has made significant contributions to the field of mitochondrial research. With a remarkable portfolio consisting of two patents, his work focuses on the intricate interactions of mitochondrial components and their implications for health and disease.
Latest Patents
Frigeri’s latest patents showcase innovative compositions and methods aimed at determining interactions of mitochondrial components. His patents specifically address the identification of agents that alter mitochondrial membrane permeability transition. The screening methods he developed are designed to detect agents that affect the interaction between the mitochondrial adenine nucleotide translocator and cyclophilin D. These agents hold promise for treating various conditions linked to altered mitochondrial function, marking a notable step forward in medical science.
Career Highlights
As a key figure at Mitokor, Inc., Luciano G. Frigeri has played a vital role in advancing research and development related to mitochondrial health. His work not only emphasizes innovation but also highlights the potential therapeutic avenues that can arise from a deeper understanding of mitochondrial interactions.
Collaborations
Frigeri has collaborated with notable colleagues in his endeavors, including Anne N. Murphy and William Christensen Clevenger. Their combined expertise continues to enhance the research and development efforts at Mitokor, Inc., fostering an environment of creativity and innovation in mitochondrial studies.
Conclusion
Luciano G. Frigeri stands as a noteworthy inventor whose contributions are shaping the future of mitochondrial research. His patents reflect a commitment to finding solutions for conditions associated with mitochondrial dysfunction, thereby advancing medical science and potentially improving patient outcomes in the years to come.